The Next Generation Biotech Media
By Daniel Ojeda, Ph.D. During the IDWeek, an annual scientific conference organized in part by the Infectious Diseases Society of America (IDSA), Vir Biotechnology will present pre-clinical efficacy and preliminary …
Read More
By Sangeeta Chakraborty, Ph.D. Indianapolis-based Eli Lilly’s leading antibody treatment for coronavirus, currently in three major clinical trials, recently came under the scrutiny of government health officials who asked the …
Read More
By Pavel Ryzhov, Ph.D. The clinical trial landscape for COVID-19 treatment options has been steadily growing as the pandemic enters the fourth quarter of 2020. Many companies, including Gilead, Regeneron, …
Read More
By Judy Ya-Hsuan Lin Cancerous tumors create highly specific conditions in their growth environment that are not present in normal tissues. Their established specificity allows researchers to develop safer therapeutic …
Read More
By T. Chakraborty, Ph.D. Osteogenesis Imperfecta (OI) is a rare disorder that affects the connective tissues in the body. It is characterized by extremely fragile bones that break easily, reduced …
Read More
By Judy Ya-Hsuan Lin Both esophageal and gastric cancers are among the top ten cancers and were responsible for over half a million new cases and deaths in 2018. According …
Read More
By Ruchi Jhonsa, Ph.D. Huntington disease is a progressive brain disorder characterized by selective loss of neurons in the striatum and cortex. This causes uncontrolled movements, emotional problems, and loss …
Read More
By T. Chakraborty, Ph.D. Alzheimer’s Disease (AD) is the most common form of dementia or, in simpler terms, loss of memory with other cognitive abilities. AD has been touted as …
Read More
By Ruchi Jhonsa, Ph.D. The experimental coronavirus vaccine developed by the University of Oxford, together with pharmaceutical giant AstraZeneca was able to generate strong T cell and antibody immune response …
Read More
By Vicky Su On July 7th, 2020, Regeneron Pharmaceuticals, Inc. announced that the Trump administration has awarded them a $4.5 billion contract to manufacture and supply REGN-COV2, an investigational antibody …
Read More